TICKERNERD
Menu
IMTXIMTXHealthcare · Biotechnology

IMTX Stock Forecast: Immatics NV Price Predictions for 2026-2027

Last close, 22 Oct 2026
$7.54
−1.95% on the day

The 9 Wall Street analysts covering Immatics NV hold a median 12-month price target of $17 — +125.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 22 Oct 2026 — in the lower half.

Market cap
$1.2B
Ticker Nerd rank
40/ 100
Median analyst target
$17
Analysts covering
9
Revenue$9.1M+93.0% y/y
Operating income−$67.2M
Net income−$62.5M
Free cash flow−$61.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.6%
1M
−15.0%
YTD
−28.2%
1Y
−25.6%
From 52W high
−36.5%
From 52W low
+12.0%
$7
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immatics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Value
74
Momentum
69
Accruals
58
Issuance
48
Size
42
Quality
33
Revisions
33
Growth
19

Volatility (77): The share price has been relatively steady.

Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25Jan 26Apr 26Jul 26Oct 26IMTXHigh $25Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $12Median $17High $25

The green dot is the last close — the median target sits +125.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026StifelInitiatesBuy$15
19 May 2026Chardan CapitalMaintainsBuy$25
19 May 2026Chardan CapitalMaintainsBuy—
28 Apr 2026TD CowenInitiatesBuy—
16 Mar 2026JefferiesAssumesBuy$18
24 Nov 2025Chardan CapitalMaintainsBuy—
19 Nov 2025MizuhoMaintainsOutperform—
18 Nov 2025GuggenheimMaintainsBuy—
18 Sept 2025GuggenheimInitiatesBuy—
28 May 2025Deutsche BankInitiatesBuy—
1 Apr 2025Cantor FitzgeraldReiteratesOverweight—
19 Nov 2024B of A SecuritiesMaintainsBuy—
7 Oct 2024Piper SandlerInitiatesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
5 Sept 2024Cantor FitzgeraldReiteratesOverweight—
16 May 2024MizuhoMaintainsBuy—
2 Nov 2023Cantor FitzgeraldInitiatesOverweight—
31 Mar 2023MizuhoInitiatesBuy—
23 Mar 2023Chardan CapitalMaintainsBuy—
10 Aug 2022Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

IMTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 22 Oct 2026, Immatics NV returned −25.6% against +15.6% for the S&P 500, dividends included.

IMTX vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26IMTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

Immatics NV (IMTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.8×

Cheaper than 28% of US stocks

Price / sales
28.1×

Cheaper than 7% of US stocks

Price / book
2.3×

Cheaper than 38% of US stocks

EV / EBITDA
−3.1×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
93.0%

Higher than 92% of US stocks

Earnings growth (YoY)
93.0%

Higher than 83% of US stocks

Gross margin
—
Operating margin
−735.0%

Higher than 6% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−47.8%

Higher than 22% of US stocks

Return on assets
−26.9%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immatics NV (IMTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immatics NV has a market value of $1.2B and an enterprise value of $755.1M.

  • Revenue in the twelve months to 30 June 2026: $41.7M. The latest quarter grew 93.0% year on year.

  • Net income over the same four quarters: −$206.5M, a −495.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$209.6M.

  • Shares outstanding: 136.7M.

  • Trailing P/E: 26.8×; forward P/E: −3.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immatics NV employs 704 people — $59K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

IMTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMTXImmatics NV$1.2B40
REPLReplimune Group, Inc.$1.1B40
VORVor Biopharma, Inc.$1.1B19
BCAXBicara Therapeutics, Inc.$1.2B54
SPTXSeaport Therapeutics, Inc.$1.1B2
SNDXSyndax Pharmaceuticals, Inc.$1.2B58
KARDKardigan, Inc.$1.2B0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immatics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMTX news & analysis

Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma

Seeking Alpha · 25 Aug 2026positive

Seeking Alpha rated Immatics N.V. as "Buy," downgraded from "Strong Buy," citing a partial partnership termination and dependence on the pivotal trial for anzu-cel, a PRAME-directed TCR therapy. Final PFS data from the phase 3 SUPRAME trial in second-line melanoma is expected in the first half of 2027, with positive phase 1b results supporting label expansion into metastatic uveal melanoma.

Why it matters — The upcoming phase 3 data readout and potential label expansion for anzu-cel represent key upcoming catalysts for Immatics' broader PRAME pipeline and its investment thesis.

Immatics Announces $150 Million Underwritten Offering

GlobeNewsWire · 25 Aug 2026neutral

Immatics announced an underwritten offering to sell 12,945,916 ordinary shares at $8.69 per share and, to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at $8.689 per warrant. The offering is expected to raise $150 million.

Why it matters — A share offering of this size will affect Immatics' share count and capital position, so IMTX watchers may monitor how the proceeds are used and how the dilution weighs on the stock.

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GlobeNewsWire · 18 Aug 2026neutral

Immatics N.V. announced its financial results for the second quarter ended June 30, 2026, and provided a business update. The announcement covers the company's clinical-stage programs in precision targeting of PRAME, spanning cell therapies and bispecifics, with activities based in Houston, Texas and Tuebingen, Germany.

Why it matters — IMTX watchers would care because the quarterly update provides the latest operational and financial status of the company's clinical-stage PRAME-targeting programs.

FAQ

Frequently asked questions about IMTX stock

What is the IMTX stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Immatics NV have a median 12-month price target of $17, with estimates ranging from $12 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMTX stock a buy right now?

Of the 9 analysts covering Immatics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immatics NV 40 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMTX?

As at 22 Oct 2026, Immatics NV ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will IMTX stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +125.5% from the last close, and Ticker Nerd's factor model ranks Immatics NV 40 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMTX stock forecast for 2030?

No analyst covering Immatics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $25 over the next 12 months.

How has IMTX stock performed over the past year?

Immatics NV returned -25.6% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immatics NV do?

Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer.

What is the latest news on IMTX?

The most recent item we track (Seeking Alpha, 25 Aug 2026): "Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma". Seeking Alpha rated Immatics N.V. as "Buy," downgraded from "Strong Buy," citing a partial partnership termination and dependence on the pivotal trial for anzu-cel, a PRAME-directed TCR therapy. Final PFS data from the phase 3 SUPRAME trial in second-line melanoma is expected in the first half of 2027, with positive phase 1b results supporting label expansion into metastatic uveal melanoma.

Company

About Immatics NV.

Immatics N.V. is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell receptor-based immunotherapies for cancer. The company develops T-cell redirecting treatments designed to help the immune system recognize and attack solid tumors, with programs spanning adoptive cell therapies and TCR bispecifics. Its current work centers on PRAME-targeted immunotherapy, a cancer-associated target used across multiple oncology applications. Immatics N.V. operates as a research-driven oncology company with a pipeline built around precision immunotherapy platforms and collaborations that support the development of next-generation cancer treatments. Headquartered in Tübingen, Germany, the company serves the broader biopharmaceutical market through its focus on novel therapies for patients with difficult-to-treat cancers.

CEO Dr. Harpreet Singh Ph.D. · 704 employees · Germany · https://www.immatics.com